Compositions of grapiprant and methods for using the same

Abstract

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

1 - 23 . (canceled) 
     
     
         24 . A pharmaceutical composition for treating pain or inflammation in a non-human animal in need thereof, comprising:
 a therapeutically effective amount of grapiprant; and   an excipient.   
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the excipient comprises one or more selected from the group consisting of lactose, sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, copovidone, surfactant, poloxamer, and sodium laurel sulfate. 
     
     
         26 . The pharmaceutical composition of  claim 25 , comprising:
 5-15% grapiprant (w/w of the total composition);   20-80% lactose (w/w of the total composition);   15-80% microcrystalline cellulose (w/w of the total composition);   1-10% sodium starch glycolate (w/w of the total composition);   1-10% copovidone (w/w of the total composition);   0.5-3% magnesium stearate (w/w of the total composition);   0.5-4% surfactant (w/w of the total composition); and   0.1-1% colloidal silicon dioxide (w/w of the total composition).   
     
     
         27 . The pharmaceutical composition of  claim 24 , further comprising 1% to 30% flavorant (w/w of the total composition). 
     
     
         28 . The pharmaceutical composition of  claim 24 , comprising 5% to 15% flavorant (w/w of the total composition). 
     
     
         29 . The pharmaceutical composition of  claim 24  formulated for oral administration. 
     
     
         30 . The pharmaceutical composition of  claim 24 , when administered to the non-human animal, achieves a C max  of grapiprant of 375 ng/mL to 10000 ng/mL at a T max  of 0.4 to 3.4 hours. 
     
     
         31 . The pharmaceutical composition of  claim 30 , when administered to the non-human animal, achieves a C max  of grapiprant of 750 ng/mL to 4000 ng/mL. 
     
     
         32 . The pharmaceutical composition of  claim 31 , when administered to the non-human animal, achieves a C max  of grapiprant of 1300 ng/mL to 4000 ng/mL. 
     
     
         33 . The pharmaceutical composition of  claim 30 , when administered to the non-human animal, achieves the C max  of grapiprant at a T max  of 0.7 to 1.7 hours. 
     
     
         34 . The pharmaceutical composition of  claim 30 , when administered to the non-human animal, achieves the C max  of grapiprant at a T max  of 0.5 to 1.0 hours. 
     
     
         35 . The pharmaceutical composition of  claim 24 , when administered to a non-human animal, provides a dosage rate of grapiprant of 1 to 10 mg per kilogram bodyweight of the non-human animal per day. 
     
     
         36 . The pharmaceutical composition of  claim 35 , when administered to a non-human animal, provides a dosage rate of grapiprant of 2 to 4 mg per kilogram bodyweight of the non-human animal per day. 
     
     
         37 . The pharmaceutical composition of  claim 24 , wherein the non-human animal is a companion animal. 
     
     
         38 . The pharmaceutical composition of  claim 37 , wherein the companion animal is a dog, cat, or horse. 
     
     
         39 - 41 . (canceled)